

2024 IOTOX SYMPOSIUM POSTER PRESENTATIONS

Basic/Translational Science

“Engineering red blood cells to sequester drugs and reduce immune-related adverse events”

Emily Henrich, Graduate Research Fellow, Bioengineering, Rice University

“Modeling immune checkpoint inhibitor-induced colitis: Mechanistic insights and therapeutic targets”

Naimah Turner, Research Assistant II, Immunology, MD Anderson Cancer Center

“Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer”

Navid Sobhani, PhD, Research Scientist, Cancer Biology, MD Anderson Cancer Center

“Immune checkpoint inhibitor induced pneumonitis occurrence, pathogenesis and management”

Rajya Devarapalli, MD, Trainee, Radiation Oncology, Andhra Medical College

“Modulating alternative splicing of GSDMB to enhance anti-tumor pyroptosis”

Zhouyihan Li, Graduate Research Assistant-GSBS, Immunology, MD Anderson Cancer Center

Clinical Research

“A retrospective study of treatment options for checkpoint-inhibitor colitis and their impact on disease outcomes”

Andres Rivera, MD, Rotating Resident, Baylor College of Medicine

“The effect of immune checkpoint inhibitor therapy on pre-existing gastroparesis and new onset of symptoms of delayed gastric emptying”

Andres Rivera, MD, Rotating Resident, Baylor College of Medicine

“Impact of implementing an immune checkpoint inhibitor educational pilot program”

Anishia Rawther-Karedath, Supervisor, APP, Genitourinary Medical Oncology, MD Anderson Cancer Center

“IOTOX related thyroid dysfunction: A quality improvement project to improve access to endocrine care and expedite normalization of thyrotropin levels”

Anne Brinkman, DNP, and **Amori Salami-Henry, DNP**, Staff, Endocrine Neoplasia & HD, MD Anderson Cancer Center

“Multisystem immunotherapy-related adverse events among patients with breast cancer treated with immune checkpoint inhibitors”

Ashwathy Balachandran Pillai, MBBS, Instructor, Hospital Medicine, MD Anderson Cancer Center

2024 IOTOX SYMPOSIUM POSTER PRESENTATIONS

Clinical Research

“Validation of endoscopic scoring system for immune checkpoint inhibitor colitis”

Carolina Colli Cruz, MD, Research Assistant II, Gastroenterology Research, MD Anderson Cancer Center

“Mystery diarrhea: A comparative analysis of immune-mediated colitis disease characteristics among patients with and without signs of inflammation on initial work-up”

Carolina Colli Cruz, MD, Research Assistant II, Gastroenterology Research, MD Anderson Cancer Center

“The impact of metformin use on the gastrointestinal toxicity and overall survival of patients treated with checkpoint inhibition”

Carolina Colli Cruz, MD, Research Assistant II, Gastroenterology Research, MD Anderson Cancer Center

“Eosinophilic colitis: A novel aggressive endoscopic presentation and its successful therapeutic management”

Carolina Colli Cruz, MD, Research Assistant II, Gastroenterology Research, MD Anderson Cancer Center

“Downbeat nystagmus after CAR T cell infusion”

Catherine Garcia, MD, Postdoctoral Fellow, Neuro-Oncology, MD Anderson Cancer Center

“Investigating sex and gender-related differences in immunotherapy treatment effects: the INSITE study”

Deanne Tibbitts, PhD, Research Assistant Professor, Oncological Sciences, Oregon Health & Science University

“Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in relapsed or refractory lymphoma”

Felipe Soto Lanza, MD, Postdoctoral Fellow, Pulmonary Medicine, MD Anderson Cancer Center

“Correlation of radiographic extent and CTCAE clinical grade in immune checkpoint inhibitor (ICI) pneumonitis and their role in predicting mortality”

Felipe Soto Lanza, MD, Postdoctoral Fellow, Pulmonary Medicine, MD Anderson Cancer Center

“Integrating genetic and radiographic markers to predict immune checkpoint inhibitor pneumonitis risk in non small cell lung cancer”

Felipe Soto Lanza, MD, Postdoctoral Fellow, Pulmonary Medicine, MD Anderson Cancer Center

“Pre-treatment monocyte counts as predictors of immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer patients”

Felipe Soto Lanza, MD, Postdoctoral Fellow, Pulmonary Medicine, MD Anderson Cancer Center

2024 IOTOX SYMPOSIUM POSTER PRESENTATIONS

Clinical Research

“A case of successful treatment of high-grade immune-mediated hepatobiliary toxicity with oral budesonide: Shifting the paradigm away from systemic steroids”

Hao Chi Zhang, MD, Assistant Professor, Gastroenterology, Hepatology, & Nutrition, MD Anderson Cancer Center

“Patterns of hospital readmissions due to immune-related adverse events (irAEs) in patients with genitourinary cancers”

Hongchao He, MD, PhD, Research Scientist, Pulmonary Medicine, MD Anderson Cancer Center

“The effect of combination therapy with PD-1 and/or PD-L1 inhibitors and statins combination therapy on overall survival and gastrointestinal toxicity”

Jay Shah, MD, Rotating Resident Baylor College of Medicine

“Checkpoint inhibition prior to stem cell transplantation increases the risk of inflammatory adverse events”

Jay Shah, MD, Rotating Resident, Baylor College of Medicine

“Patterns of immune-related adverse events (irAEs) and responses in adolescents and young adults with melanoma receiving immune checkpoint inhibitors (ICIs) during initial treatment and rechallenge”

Jiasen He, MBBS, Fellow, Pediatrics, MD Anderson Cancer Center

“Disease flare following immune checkpoint inhibition in patients with cancer and preexisting vasculitis”

Juan Sevillano Gutierrez, MD, Coordinator, Research Data, General Internal Medicine Research, MD Anderson Cancer Center

“Use of immune checkpoint inhibitors in patients with cancer and preexisting lupus erythematosus”

Juan Sevillano Gutierrez, MD, Coordinator, Research Data, General Internal Medicine Research, MD Anderson Cancer Center

“Atypical presentations of immune checkpoint inhibitor colitis on 18-FDG PET/CT: A case series”

Kei Takigawa, MD, Rotating Resident, Baylor College of Medicine

“Gastrointestinal infection before immune checkpoint inhibition hinders treatment efficacy and increases the risk of checkpoint inhibitor-related colitis”

Kian Abdul-Baki, DO, Assistant Professor, Internal Medicine, University of Texas Medical Branch

“Aggressive behavior of immune-mediated toxicities following immune checkpoint inhibitor therapy rechallenge”

Krishnavathana Varatharajalu, MD, Coordinator, Clinical Studies, Gastroenterology Research, MD Anderson Cancer Center

2024 IOTOX SYMPOSIUM POSTER PRESENTATIONS

Clinical Research

“Increased sleep disruption in patients with advanced cancer undergoing immunotherapy”

Kshama Bhyravabhotla, MD, Rotating Fellow, Pulmonary and Critical Care, University of Texas Health Sciences Center at Houston

“Immune checkpoint therapy (ICT) rechallenge after immune-mediated myocarditis”

Lily Chen, MD, Rotating Resident, Cancer Medicine, MD Anderson Cancer Center

“The when, the where, and the how: Temporal and quantitative trends in fecal calprotectin levels and the implications for checkpoint-inhibitor colitis”

Linfeng Lu, Rotating Resident, Baylor College of Medicine

“Baseline prescription rate of Pneumocystis Jirovecii Pneumonia prophylaxis for cancer patients on glucocorticoids for Immune-Checkpoint Inhibitor induced toxicity at hospital discharge”

Maggie Lu, PharmD, Clinical Pharmacy Specialist, Hospital Medicine, MD Anderson Cancer Center

“Tackling TIL therapy challenges in COVID-19 patients”

Mamtha Balla, MD, Fellow, Infectious Diseases, MD Anderson Cancer Center

“Use of infliximab in grade III/IV ICI induced nephritis”

Masroor Habeeb, MBBS, Graduate Research Assistant, Nephrology, MD Anderson Cancer Center

“Small cell, big challenge: Managing tarlatamab-induced cytokine release syndrome in extensive stage disease”

Mitchell Parma, MD, Fellow, Cancer Medicine, MD Anderson Cancer Center

“Recent abdominal surgery as a risk factor for unfavorable immune-mediated colitis outcomes”

Rohan Ahuja, MD, Rotating Resident, Cancer Medicine Fellowship Program, MD Anderson Cancer Center, Internal Medicine, UTHealth

“Worse survival and gastrointestinal toxicity outcomes among checkpoint inhibitor-treated patients receiving proton pump inhibitors”

Samanthika Devalaraju, MD, Rotating Resident, Baylor College of Medicine

“The impact of fecal diversion on immune checkpoint inhibitor adverse GI toxicities”

Sidra Naz, MD, Research Assistant II, Gastroenterology Research, MD Anderson Cancer Center

“Mechanistic insights on immune checkpoint inhibitor-induced recurrent inflammatory arthritis”

Synat Keam, PhD, Postdoctoral Fellow, Immunology, MD Anderson Cancer Center

2024 IOTOX SYMPOSIUM POSTER PRESENTATIONS

Clinical Research

“Helicobacter pylori infection negatively affects response of gastric cancer to immunotherapy Running head: HP impairs ICI efficacy in gastric cancer”

Yinghong (Mimi) Wang, MD, PhD, Professor,
Gastroenterology, Hepatology, & Nutrition,
MD Anderson Cancer Center

“Gastrointestinal infection prior to immune checkpoint inhibition hinders treatment efficacy and increases the risk for checkpoint-inhibitor colitis”

Yinghong (Mimi) Wang, MD, PhD, Professor,
Gastroenterology, Hepatology, & Nutrition,
MD Anderson Cancer Center

“Novel endoscopic scoring system for immune mediated colitis shows promise for guiding medical management: A Multicenter Retrospective Analysis of 674 Patient”

Yinghong (Mimi) Wang, MD, PhD, Professor,
Gastroenterology, Hepatology, & Nutrition,
MD Anderson Cancer Center